Solh Melhem, Bashey Asad, Zhang Xu, Holland H Kent, Bachier-Rdriguez Lizamarie, Morris Lawrence E, Solomon Scott R
Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.
Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.
Transplant Cell Ther. 2024 Jun;30(6):607.e1-607.e8. doi: 10.1016/j.jtct.2024.03.025. Epub 2024 Mar 27.
The development of chronic graft-versus-host disease (GVHD) in 1-year survivors after matched related or unrelated hematopoietic cell transplantation was shown to be associated with higher nonrelapse mortality (NRM) and worse overall survival (OS). The impact of chronic GVHD requiring immunosuppression (IS) for recipients of haploidentical transplantation (HIDT) with post-transplantation cyclophosphamide (PTCy) who have survived to 1 year post-transplantation has not been studied previously and was investigated for this analysis. A total of 322 adult patients who underwent HIDT at our center were included in this study. The effect of IS-free status on post-transplantation outcomes was assessed. The median follow-up for survivors was 63.9 months (range, 18.3 to 165 months). A total of 163 patients (65%) were IS-free at 1 year post-HIDT. Baseline characteristics of this group were similar to those of patients still requiring IS, except for higher percentages of female donor-male recipient pairs (28% versus 15%; P =.03) and female donors (48% versus 30%; P =.008). Logistic regression to identify patients more likely to be on IS at 1 year post-HIDT identified the use of a female donor as a significant risk factor (odds ratio, 2.11; P = .009). In a Cox regression analysis, patients requiring IS at 1 year post-transplantation had higher NRM (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.80 to 6.72; P < .001) and showed a trend toward worse disease-free survival (DFS) (HR, 1.59; 95% CI, .95 to 2.66; P =.08), with no impact on OS (HR, 1.44; 95% CI, .90 to 2.31; P = .13) or relapse (HR, .77; 95% CI, .37 to 1.61; P = .49). These results indicate that use of a female donor is a significant risk factor for requiring IS at 1 year post-HIDT. Additionally, chronic GVHD requiring IS at 1-year post-HIDT no significant effect on relapse but is associated with higher NRM and a trend toward worse DFS.
在匹配的亲属或非亲属造血细胞移植后1年存活者中,慢性移植物抗宿主病(GVHD)的发生与较高的非复发死亡率(NRM)和较差的总生存期(OS)相关。对于接受单倍体移植(HIDT)并使用移植后环磷酰胺(PTCy)且存活至移植后1年的患者,需要免疫抑制(IS)的慢性GVHD的影响此前尚未进行研究,本分析对此进行了调查。本研究纳入了在我们中心接受HIDT的322例成年患者。评估了无IS状态对移植后结局的影响。存活者的中位随访时间为63.9个月(范围为18.3至165个月)。共有163例患者(65%)在HIDT后1年时处于无IS状态。该组的基线特征与仍需要IS的患者相似,但女性供体-男性受体配对的比例更高(28%对15%;P = 0.03),女性供体的比例也更高(48%对30%;P = 0.008)。通过逻辑回归确定在HIDT后1年更可能接受IS治疗的患者,结果显示使用女性供体是一个显著的风险因素(比值比,2.11;P = 0.009)。在Cox回归分析中,移植后1年需要IS的患者具有更高的NRM(风险比[HR],4.18;95%置信区间[CI],1.80至6.72;P < 0.001),并且无病生存期(DFS)有变差的趋势(HR,1.59;95%CI,0.95至2.66;P = 0.08),对OS无影响(HR,1.44;95%CI,0.90至2.31;P = 0.13),对复发也无影响(HR,0.77;95%CI,0.37至1.61;P = 0.49)。这些结果表明,使用女性供体是HIDT后1年需要IS的一个显著风险因素。此外,HIDT后1年需要IS的慢性GVHD对复发无显著影响,但与较高的NRM以及DFS变差的趋势相关。